Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


InnoSkel Targets Rapid UK Patient Access For Gene Therapy

INS-101 Is Intended For Rare Bone Disorder

Executive Summary

The number of “innovation passports” handed out by the UK Medicines and Healthcare products Regulatory Agency is growing as more companies seek to take advantage of the tools and flexibilities available under the ILAP. InnoSkel is one such company.

You may also be interested in...

UK Regulator Issues 41 ‘Innovation Passports’ In First Year Of New Pathway

The UK’s ILAP, a post-Brexit scheme introduced in 2021 to accelerate the development of, and access to, new innovative medicines, proved popular in its first year of operation. A total of 71 applications were received last year from companies wanting to take advantage of the regulatory advice, tools and flexibilities on offer.

The Story So Far: The UK’s New Licensing And Access Pathway

As the UK’s new pathway for innovative drugs approaches the end of its first year of operation, representatives of the national regulatory agency and England’s HTA body assess progress so far, including the greater role assigned to patients in the system.

Rare Disease Body Wants EU Legislative Overhaul To Address Orphan Definitions & Incentives

Eurordis has welcomed some parts of the leaked proposals for overhauling the EU medicines legislation, but it has a number of concerns, including the future role of patient representatives if the European Medicines Agency’s committee structure is slimmed down as planned.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts